Abstract: A display device includes pixels including a light-emitting element, and an initialization transistor connected between an anode electrode of the light-emitting element and a first initialization power line to which a voltage of initialization power is supplied, and turned on when an initialization scan signal is supplied, and an initialization scan driver which supplies the initialization scan signal. The initial scan driver supplies an i-th (i is a natural number) initial scan signal to overlap an (i?1)-th initial scan signal, and supplies an (i+1)-th initial scan signal so as not to overlap the i-th initial scan signal, and the initialization scan signal is set to a gate-on voltage.

Abstract: A display apparatus includes a base substrate, a light emitting structure disposed on the base substrate, and a thin film encapsulation layer disposed on the light emitting structure and including at least one inorganic layer and at least one organic layer. The at least one inorganic layer includes a high density layer having a density of greater than or equal to about 2.0 g/cm3 and a low density layer having a density of less than about 2.0 g/cm3. The high density layer and the low density layer are in contact with each other.

Abstract: An embodiment of the invention provides a display device including a display panel including corner portions having cut patterns defined by cut portions. The display panel includes a substrate, a light-emitting element including a pixel electrode, an emissive layer and a common electrode and disposed on the substrate in the cut pattern, a first inorganic encapsulation layer disposed on the common electrode in the cut pattern; an organic encapsulation layer disposed on the first inorganic encapsulation layer in the cut pattern; and an organic pattern disposed on the substrate in the cut portions.

Abstract: The present invention relates to a reduced-graphene-oxide/silicon-metal-particle composite, a method of manufacturing the composite and an electrode for a secondary battery including the composite. The method of manufacturing the reduced-graphene-oxide/silicon-metal-particle composite includes preparing a reduced-graphene-oxide dispersion solution by reducing graphene oxide formed through cation-pi interaction, preparing a reduced-graphene-oxide/silicon-metal-particle dispersion solution by mixing the reduced-graphene-oxide dispersion solution with silicon metal particles, and manufacturing a composite powder having a core-shell structure by drying the reduced-graphene-oxide/silicon-metal-particle dispersion solution. Thereby, reduced graphene oxide can be formed using the graphene oxide dispersion solution having few defects and high purity obtained through cation-pi interaction, and dried to afford a composite powder having a core-shell structure, which is applicable to an electrode for a secondary battery.

Abstract: A method of fabricating the organic-inorganic hybrid coating layer includes: preparing a gel mixture including an organic precursor and colloidal silica particles; preparing a first mixed solution by heating the gel mixture; preparing a second mixed solution by adding quantum dots to the first mixed solution; and coating the second mixed solution on a substrate and irradiating light thereon to form a polymer matrix in which the organic precursor and the colloidal silica particles are crosslinked, and preparing a coating layer in which the quantum dots are dispersed in the polymer matrix, wherein the organic precursor may include at least one of dipentaerythritol pentaacrylate (DPPA) or dipentaerythritol hexaacrylate (DPHA).

Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

Abstract: Disclosed is a method of preparing a pH-sensitive controlled-release emulsion hydrogel using chitosan and pectin. More particularly, disclosed is a method of preparing a pH-sensitive controlled-release emulsion hydrogel that is capable of entrapping various substances to be encapsulated and is stable in gastrointestinal conditions, but upon exposure to neutral pH after passing through the stomach, releases the entrapped emulsion in response to the pH.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: A display device includes a first substrate, a second substrate disposed on the first substrate, a display disposed on the first substrate, a sealant disposed between the first substrate and the second substrate along an outer portion of the second substrate and attaching the first substrate to the second substrate together, and a filler disposed in a space defined by the first substrate, the second substrate and the sealant. The filler is spaced apart from an inner surface of the sealant with an empty space disposed therebetween. An edge of the filler is inclined with respect to a first surface of the second substrate.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: A display apparatus includes a base substrate, a light emitting structure disposed on the base substrate, and a thin film encapsulation layer disposed on the light emitting structure and including at least one inorganic layer and at least one organic layer. The at least one inorganic layer includes a high density layer having a density of greater than or equal to about 2.0 g/cm3 and a low density layer having a density of less than about 2.0 g/cm3. The high density layer and the low density layer are in contact with each other.

Abstract: A display apparatus includes a base substrate, a light emitting structure disposed on the base substrate, and a thin film encapsulation layer disposed on the light emitting structure and including at least one inorganic layer and at least one organic layer. The at least one inorganic layer includes a high density layer having a density of greater than or equal to about 2.0 g/cm3 and a low density layer having a density of less than about 2.0 g/cm3. The high density layer and the low density layer are in contact with each other.

Abstract: An embodiment of the invention provides a display device including a display panel including corner portions having cut patterns defined by cut portions. The display panel includes a substrate, a light-emitting element including a pixel electrode, an emissive layer and a common electrode and disposed on the substrate in the cut pattern, a first inorganic encapsulation layer disposed on the common electrode in the cut pattern; an organic encapsulation layer disposed on the first inorganic encapsulation layer in the cut pattern; and an organic pattern disposed on the substrate in the cut portions.

Abstract: A display device may include a substrate and a light emitting element disposed on the substrate. An encapsulation layer covers the light emitting element. The encapsulation layer includes at least two inorganic encapsulation layers and at least one organic encapsulation layer. The at least one organic encapsulation layer includes a first organic material having a permittivity less than or equal to about 3.0. A low permittivity layer is disposed on the encapsulation layer. The low permittivity layer includes a second organic material and first hollow particles dispersed in the second organic material. An input sensing layer is disposed on the low permittivity layer.

Abstract: A method of fabricating the organic-inorganic hybrid coating layer includes: preparing a gel mixture including an organic precursor and colloidal silica particles; preparing a first mixed solution by heating the gel mixture; preparing a second mixed solution by adding quantum dots to the first mixed solution; and coating the second mixed solution on a substrate and irradiating light thereon to form a polymer matrix in which the organic precursor and the colloidal silica particles are crosslinked, and preparing a coating layer in which the quantum dots are dispersed in the polymer matrix, wherein the organic precursor may include at least one of dipentaerythritol pentaacrylate (DPPA) or dipentaerythritol hexaacrylate (DPHA).

Abstract: The present disclosure provides a quantum dot thin film that is formed by cross-linking ligands of quantum dots with a photo cross-linker containing two or more azide groups. According to still another aspect of the present disclosure, a method for forming a quantum dot pattern includes: forming a quantum dot layer on a substrate by coating the substrate with a solution including quantum dots and a photo cross-linker containing two or more azide groups; placing a mask having a pattern on the quantum dot layer and performing UV exposure on the quantum dot layer; and forming a quantum dot pattern by removing a non-exposed region of the quantum dot layer.

Abstract: A display device may include a substrate and a light emitting element disposed on the substrate. An encapsulation layer covers the light emitting element. The encapsulation layer includes at least two inorganic encapsulation layers and at least one organic encapsulation layer. The at least one organic encapsulation layer includes a first organic material having a permittivity less than or equal to about 3.0. A low permittivity layer is disposed on the encapsulation layer. The low permittivity layer includes a second organic material and first hollow particles dispersed in the second organic material. An input sensing layer is disposed on the low permittivity layer.

Abstract: A display apparatus includes a base substrate, a light emitting structure disposed on the base substrate, and a thin film encapsulation layer disposed on the light emitting structure and including at least one inorganic layer and at least one organic layer. The at least one inorganic layer includes a high density layer having a density of greater than or equal to about 2.0 g/cm3 and a low density layer having a density of less than about 2.0 g/cm3. The high density layer and the low density layer are in contact with each other.

Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Abstract: A secondary battery using a vanadium oxide as a positive electrode active material is provided. The secondary battery is prevented from degradation of capacity by preventing dissolution of vanadium. The vanadium oxide includes secondary particles formed by assemblage of primary particles.